Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Moderna Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss decreased by 4.2% to $271.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 80.0%, from $1.36B to $271.00M. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss shows an upward trend with a 310.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase indicates that a significant portion of the portfolio is suffering from prolonged valuation declines, raising concerns about potential future write-downs.
Detailed definition
The cumulative amount of unrealized losses for debt securities that have been in a continuous loss position for 12 month...
Peer comparison
Standard disclosure for insurance companies to track the aging of unrealized losses.
other_debt_securities_available_for_sale_continuous_unre_23ad4cHistorical Data
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00M | $1.00M | $517.00M | $3.65B | $5.52B | $7.70B | $8.15B | $7.40B | $6.64B | $5.10B | $4.80B | $3.58B | $2.64B | $1.36B | $567.00M | $499.00M | $283.00M | $271.00M |
| QoQ Change | — | +0.0% | >999% | +605.2% | +51.5% | +39.4% | +5.9% | -9.2% | -10.2% | -23.3% | -5.8% | -25.5% | -26.1% | -48.7% | -58.2% | -12.0% | -43.3% | -4.2% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | +103.0% | +20.3% | -33.8% | -41.1% | -51.7% | -60.2% | -73.4% | -88.2% | -86.1% | -89.3% | -80.0% |
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss at Other Companies
Frequently Asked Questions
- What is Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Moderna (MRNA) reported debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss of $271.00M in Q1 2026.
- How has Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss changed year-over-year?
- Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss decreased by 80.0% year-over-year, from $1.36B to $271.00M.
- What is the long-term trend for Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Over 4 years (2021 to 2025), Moderna's debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss has grown at a 310.2% compound annual growth rate (CAGR), from $1.00M to $283.00M.
- What does debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss mean?
- The total dollar amount of paper losses on debt securities that have been losing value for at least a year.